|Page (1) of 1 - 06/11/18||email article||print page|
Summit Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018(June 11, 2018)
- Highlights the Power of the Discuva Platform to Identify Novel Antibiotic Targets
OXFORD, United Kingdom and CAMBRIDGE, Mass., June 11, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces the discovery of a second novel target to kill the bacteria Neisseria gonorrhoeae. The new target, identified using Summit’s Discuva Platform, is distinct from that of existing antibiotics and also from Summit’s recently announced lead series of new mechanism antibiotics for gonorrhoea.
Summit also reports the discovery of a promising new series of compounds against this second target. This series of compounds have the characteristics the Company believes are required for a treatment of gonorrhoea by combining high potency with selective targeting of N. gonorrhoeae, including resistant strains.
This research was showcased as part of Summit’s presentations at the ASM Microbe 2018 congress in Atlanta, US. Summit also reported preclinical data at this congress on its lead gonorrhoea series from which it expects to nominate a candidate to advance into IND enabling studies during the second half of 2018.
“Gonorrhoea poses an urgent threat as the world approaches an era of untreatable disease due to increasing resistance against the last recommended treatment option,” commented Dr David Roblin, Summit’s President of Research and Development. “Having two novel approaches with the potential to combat gonorrhoea means Summit has an opportunity to meaningfully contribute to the fight against this significant worldwide health threat.”
Both series of compounds were identified with Summit’s Discuva Platform, a proprietary genetics-based technology for the discovery and development of new antibiotics against multiple pathogens associated with antibiotic resistance.
“We believe our Discuva Platform has the potential to radically change antibiotic drug discovery and development,” added Dr Roblin. “Gonorrhoea is the first pathogen we are targeting with our platform to bring forward new mechanism antibiotics. Exploiting new bacterial targets will be critical to ensure we are developing potential new standards of care treatments that are capable of achieving commercial success.”
Copies of all the presentations given at ASM Microbe 2018 are available in the publications section of the Company’s website, www.summitplc.com.
It is estimated by the World Health Organization (‘WHO’) that there are approximately 78 million new cases of gonorrhoea globally per year. Neisseria gonorrhoeae has consistently developed resistance to each class of antibiotics recommended for treatment and there is now only one treatment recommended by the Centers for Disease Control, a combination of two antibiotics which is approaching the point at which its use should be stopped. There are currently no other recommended antibiotics that can be effectively deployed to target the disease. The WHO ranks as “High” the priority of R&D investment into the search for antibiotics which are effective against N. gonorrhoeae.
About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications in neuromuscular and infectious diseases for which there are no existing or only inadequate therapies. Summit is currently conducting clinical programmes focused on the neuromuscular disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
|Glyn Edwards / Richard Pye (UK office)||Tel:||44 (0)1235 443 951|
|Erik Ostrowski / Michelle Avery (US office)||+1 617 225 4455|
|Cairn Financial Advisers LLP (Nominated Adviser)||Tel:||+44 (0)20 7213 0880|
|Liam Murray / Tony Rawlinson|
|N+1 Singer (Joint Broker)||Tel:||+44 (0)20 7496 3000|
|Aubrey Powell / Jen Boorer|
|Panmure Gordon (Joint Broker)||Tel:||+44 (0)20 7886 2500|
|Freddy Crossley, Corporate Finance|
|MacDougall Biomedical Communications (US)||Tel:||+1 781 235 3060|
|Karen Sharma||[email protected]|
|Consilium Strategic Communications (UK)||Tel:||+44 (0)20 3709 5700|
|Mary-Jane Elliott / Jessica Hodgson /||[email protected]|
|Lindsey Neville / Philippa Gardner|
Summit Forward-looking Statements